Skip to main content

Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

The Original Article was published on 24 January 2005

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].

References

  1. 1.

    Carey PD, Vythilingum B, Seedat S, Muller JE, van AM, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005, 5: 5-10.1186/1471-244X-5-5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000, 68: 29-39. 10.1016/S0024-3205(00)00911-5.

    CAS  Article  PubMed  Google Scholar 

Pre-publication history

  1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/5/44/prepub

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Paul D Carey.

Additional information

The online version of the original article can be found at 10.1186/1471-244X-5-5

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Carey, P.D., Vythilingum, B., Seedat, S. et al. Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5, 44 (2005). https://doi.org/10.1186/1471-244X-5-44

Download citation